Trimming Trem2 and possible impacts on the metabolic syndrome

Leshem, Avner; Elinav, Eran

doi:10.1113/jp283781

Our system is currently under heavy load due to increased usage. We're actively working on upgrades to improve performance. Thank you for your patience.

The Journal of Physiology

2022

DOI: 10.1113/jp283781

|View full text |Cite

Trimming Trem2 and possible impacts on the metabolic syndrome

Avner Leshem

Eran Elinav

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Preprint1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 7 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Targeting TREM2 to disrupt the mitochondrial lipid and iron metabolism in cisplatin-resistant gastric cancer cells

Wang,

Guo,

et al. 2023

Preprint

View full text Add to dashboard Cite

Cancer cells compete with tumor associated macrophages for iron, especially for drug resistant tumor cells. But how drug resistant tumor cells compete with immunosuppressive macrophages in tumor microenvironment is unclear. Here, we identified the triggering receptor expressed on myeloid cells 2 (TREM-2) as a signaling hub that orchestrates lipid and iron metabolism, and immune evasion. TREM-2 was expressed only on cisplatin resistant gastric cancer cell lines, but not on normal gastric epithelial cells and gastric cancer cells. Suppressing TREM2 reversed the drug resistance in vitro and slowed down tumor growth in vivo. Mechanically, TREM2 facilitated TFR1-mediated iron endocytosis to fuel the mitochondria for integrated membrane potential and ATP output. Furthermore, TREM2 knockdown lead to STING upregulation and promote the downstream cytokines IL6, IL-1β secretion. Collectively, our study identified TREM2 as a signaling hub that orchestrates lipid and iron metabolism and immune evasion in cisplatin resistant cells, and explains the complicated metabolic and immune signature for tumor drug resistance.

show abstract

Targeting TREM2 to disrupt the mitochondrial lipid and iron metabolism in cisplatin-resistant gastric cancer cells

Wang,

Guo,

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Trimming Trem2 and possible impacts on the metabolic syndrome

Cited by 1 publication

References 7 publications

Targeting TREM2 to disrupt the mitochondrial lipid and iron metabolism in cisplatin-resistant gastric cancer cells

Targeting TREM2 to disrupt the mitochondrial lipid and iron metabolism in cisplatin-resistant gastric cancer cells

Contact Info

Product

Resources

About